|
Myopathy
|
0.500 |
GeneticVariation
|
group |
GWASCAT |
Genomewide Association Study of Statin-Induced Myopathy in Patients Recruited Using the UK Clinical Practice Research Datalink.
|
31220337 |
2019 |
|
Myopathy
|
0.500 |
GeneticVariation
|
group |
BEFREE |
The data highlight the role of SLCO1B1 c.521C>T SNP as a replicable genetic risk factor for statin myopathy.
|
31220337 |
2019 |
|
Myopathy
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Our findings reveal that SLCO1B1 and ABCB1 genetic variants are associated with statin-induced myopathy.
|
31298164 |
2019 |
|
Myopathy
|
0.500 |
GeneticVariation
|
group |
BEFREE |
A case of simvastatin-induced myopathy with SLCO1B1 genetic predisposition and co-ingestion of linagliptin and Stevia rebaudiana.
|
30714173 |
2019 |
|
Myopathy
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Effects of SLCO1B1 and GATM gene variants on rosuvastatin-induced myopathy are unrelated to high plasma exposure of rosuvastatin and its metabolites.
|
29950617 |
2019 |
|
Myopathy
|
0.500 |
Biomarker
|
group |
BEFREE |
The promotion on hepatic uptake of statins mediated by OATP1B1 might lead to enhanced efficacy of cholesterol lowering and reduced risk of myopathy for hyperlipidemia patients when given statins together with deoxyschizandrin or schizandrin B.
|
29405807 |
2019 |
|
Myopathy
|
0.500 |
Biomarker
|
group |
BEFREE |
Statin-induced myopathy SLCO1B1 521T > C is associated with prediabetes, high body mass index and normal lipid profile in Emirati population.
|
29534995 |
2018 |
|
Myopathy
|
0.500 |
GeneticVariation
|
group |
BEFREE |
The findings of this study indicated that SLCO1B1 T521C was associated with a significantly higher risk of statin-induced myopathy, especially for simvastatin, rosuvastatin, and cerivastatin.
|
30250148 |
2018 |
|
Myopathy
|
0.500 |
Biomarker
|
group |
BEFREE |
Many studies have focused on the consequences of OATP1B1 variants to statin disposition in vitro and in vivo and would suggest that genetic variability in SLCO1B1 has important implications for statin pharmacokinetics, risk for statin-induced myopathy, and modulation of statin treatment response.
|
27936281 |
2017 |
|
Myopathy
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Only SLCO1B1, not ABCB1 genotype, is likely to be associated with simvastatin-induced myopathy.
|
28350522 |
2017 |
|
Myopathy
|
0.500 |
GeneticVariation
|
group |
BEFREE |
SLCO1B1 polymorphism is not associated with risk of statin-induced myalgia/myopathy in a Czech population.
|
25992810 |
2015 |
|
Myopathy
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Case-control studies investigating the association between SLCO1B1 gene T521C polymorphism and statin-related myopathy risk were included.
|
26376374 |
2015 |
|
Myopathy
|
0.500 |
GeneticVariation
|
group |
BEFREE |
SLCO1B1 polymorphisms are strongly associated with statin-induced myopathy whereas few studies have assessed their effect on statin differential response.
|
24668570 |
2014 |
|
Myopathy
|
0.500 |
Biomarker
|
group |
BEFREE |
This article is an update to the 2012 Clinical Pharmacogenetics Implementation Consortium guideline for SLCO1B1 and simvastatin-induced myopathy.
|
24918167 |
2014 |
|
Myopathy
|
0.500 |
Biomarker
|
group |
BEFREE |
Aim of this review is: (i) to describe the molecular mechanisms associated to statin induced myopathy including defects in isoprenoids synthesis followed by altered prenylation of small GTPase, such as Ras and Rab proteins; (ii) to present the emerging aspects on pharmacogenetics, including CYP3A4, OATP1B1 and glycine amidinotransferase (GATM) polymorphisms impacting either statin bioavailability or creatine synthesis; (iii) to summarize the available epidemiological evidences; and (iii) to discuss the concepts that would be of interest to the clinicians for the daily management of patients with statin induced myopathy.
|
24835295 |
2014 |
|
Myopathy
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Common genetic variation does not appear to be an important determinant of statin response, with the exception of SLCO1B1 and risk of myopathy.
|
25313593 |
2014 |
|
Myopathy
|
0.500 |
GeneticVariation
|
group |
BEFREE |
To-date only polymorphisms in the SLCO1B1 gene, which encodes the protein responsible for hepatic uptake of statins, and the COQ2 gene, important in the synthesis of coenzyme Q10, have been validated as being strongly associated with statin-induced myopathy.
|
24176465 |
2014 |
|
Myopathy
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Among the genetic factors evaluated, statin-related myopathy appears to be most strongly associated with variants in SLCO1B1.
|
24810685 |
2014 |
|
Myopathy
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Polymorphisms in the solute carrier organic anion transporter 1B1 (SLCO1B1) gene is associated with increased statin exposure and simvastatin-induced myopathy.
|
23579966 |
2013 |
|
Myopathy
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Our data replicate the association of SLCO1B1 variants with statin-induced myopathy.
|
23942138 |
2013 |
|
Myopathy
|
0.500 |
Biomarker
|
group |
BEFREE |
The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy.
|
22617227 |
2012 |
|
Myopathy
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Intronic variants in SLCO1B1 related to statin-induced myopathy are associated with the low-density lipoprotein cholesterol response to statins in Chinese patients with hyperlipidaemia.
|
22668755 |
2012 |
|
Myopathy
|
0.500 |
Biomarker
|
group |
CTD_human |
Our findings provide further support for a role for SLCO1B1 genotype in simvastatin-associated myopathy, and suggest that this association may be stronger for simvastatin compared with atorvastatin.
|
21243006 |
2012 |
|
Myopathy
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Our objective is to report on two cases of statin-induced myopathy occurring in a family with two patients who are carriers of the loss of function SLCO1B1 genetic variant and to briefly review the related literature.
|
22582980 |
2012 |
|
Myopathy
|
0.500 |
Biomarker
|
group |
BEFREE |
Through genome-wide association studies, it has become clear that SLCO1B1 is among the strongest PK predictors of myopathy risk.
|
22462750 |
2012 |